書誌情報
LBA-7. Talquetamab, a GPRC5D * CD3 Bispecific Antibody, in Japanese Patients With Relapsed / Refractory Multiple Myeloma : Updated Results From the Phase 1/2 MonumenTAL-1 Study
Shigeki Ito1, Yoshiaki Kuroda2, Kazutaka Sunami3, Kosei Matsue4, Kazunori Imada5, Hideto Tamura6, Manami Takizawa7, Marimo Takahashi7, Mikihiro Takamoto7, Lixia Pei8, Xiang Qin9, Tara J Masterson9, Michela Campagna10, Veronique Vreys11, Bonnie W Lau9, Yusuke Izumi7, Yasushi Takamatsu12
1Division of Hematology & Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, 2NHO, Hiroshimanishi Medical Center, 3NHO, Okayama Medical Center, 4Kameda Medical Center, 5Japanese Red Cross Osaka Hospital, 6Dokkyo Medical University Saitama Medical Center, 7Johnson & Johnson, Tokyo, 8Johnson & Johnson, Raritan, 9Johnson & Johnson, Spring House, 10Johnson & Johnson, Madrid, 11Johnson & Johnson, Beerse, 12Fukuoka University Hospital
International Journal of Myeloma 15(3): 108-108, 2025.
個人会員・法人会員の方（IDが5または10で始まる方）
- 全文ダウンロード： 従量制、基本料金制の方共に121円(税込) です。
